Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China
- 1 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 42 (6), 1658-1664
- https://doi.org/10.1161/strokeaha.110.604249
Abstract
Background and Purpose—: Little is known about intravenous recombinant tissue plasminogen activator (rtPA) use in China. By accessing the Chinese National Stroke Registry (CNSR), the rate of intravenous rtPA use was reviewed. We specifically examined the issues of prehospital and in-emergency department delay and compared them with the published data from developed countries. Methods—: Funded by Chinese government, CNSR is the only nationwide stroke registry that includes 132 urban hospitals. All patients eligible for intravenous rtPA were included for analysis. We then compared the onset-to-needle time and door-to-needle time in the emergency department in China with those in developed countries. Results—: From September 2007 to August 2008, 14 702 patients with ischemic stroke were entered into CNSR. Among 11 675 patients with known time of stroke onset, 2514 (21.5%) presented to the emergency department within 3 hours, 1469 (12.6%) were eligible for thrombolytic treatment, and 284 (2.4%) were finally treated, 181 (1.6%) of them with intravenous rtPA. The median onset-to-needle time was 180 (interquartile range, 150 to 228) minutes; the median door-to-needle time was 116 (interquartile range, 70 to 150) minutes; the median imaging-to-needle time was 90 (interquartile range, 60 to 129) minutes. Patients who were younger, presented to the emergency department quicker, with higher National Institutes of Health Stroke Scale scores, having higher income, and better education had a better chance of receiving intravenous rtPA. Conclusions—: Approximately 1 in 5 patients with stroke presenting within 3 hours received thrombolytic therapy. The onset-to-needle time, door-to-needle time, and especially imaging-to-needle time were significantly longer than those in developed countries. Reducing prehospital and in-emergency department response time would help increase intravenous rtPA use in China.Keywords
This publication has 17 references indexed in Scilit:
- Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modellingThe Lancet Neurology, 2009
- Burden of Stroke in ChinaInternational Journal of Stroke, 2007
- Stroke in China: epidemiology, prevention, and management strategiesThe Lancet Neurology, 2007
- IV tissue plasminogen activator use in acute strokeNeurology, 2006
- Acute Stroke Care in the USStroke, 2005
- Intravenous Tissue Plasminogen Activator for Acute Stroke in California: Recipients and ResourcesCerebrovascular Diseases, 2004
- Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic StrokeStroke, 2004
- Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic StrokeArchives of Neurology, 2001
- Why are stroke patients excluded from TPA therapy?Neurology, 2001
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995